Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) major shareholder Bioventures 2018 L.P. Mpm sold 3,733 shares of Entrada Therapeutics stock in a transaction on Friday, August 28th. The shares were sold at an average price of $7.01, for a total transaction of $26,168.33. Following the completion of the sale, the insider directly owned 4,275,693 shares of the company's stock, valued at approximately $29,972,607.93. This trade represents a 0.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.
Bioventures 2018 L.P. Mpm also recently made the following trade(s):
- On Monday, August 31st, Bioventures 2018 L.P. Mpm sold 44,259 shares of Entrada Therapeutics stock. The stock was sold at an average price of $6.99, for a total value of $309,370.41.
- On Thursday, August 27th, Bioventures 2018 L.P. Mpm sold 38,922 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.20, for a total value of $280,238.40.
Entrada Therapeutics Trading Up 0.7%
NASDAQ TRDA opened at $7.05 on Tuesday. The company has a market cap of $274.53 million, a P/E ratio of -1.78 and a beta of -0.26. The company has a fifty day simple moving average of $7.08 and a 200 day simple moving average of $9.28. Entrada Therapeutics, Inc. has a 12-month low of $5.02 and a 12-month high of $16.45.
Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.04). The business had revenue of $0.90 million for the quarter, compared to the consensus estimate of $2.32 million. Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%. Sell-side analysts predict that Entrada Therapeutics, Inc. will post -4.03 EPS for the current year.
Analyst Upgrades and Downgrades
A number of brokerages have issued reports on TRDA. Roth Capital reaffirmed a "buy" rating and issued a $11.00 price objective on shares of Entrada Therapeutics in a research report on Wednesday, August 12th. HC Wainwright cut Entrada Therapeutics from a "buy" rating to a "neutral" rating in a research note on Friday, May 8th. Guggenheim decreased their price objective on shares of Entrada Therapeutics from $20.00 to $17.00 and set a "buy" rating for the company in a report on Monday, June 8th. Finally, Weiss Ratings downgraded shares of Entrada Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Thursday, August 13th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $17.75.
Check Out Our Latest Stock Analysis on Entrada Therapeutics
Institutional Trading of Entrada Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Odyssean LLC purchased a new stake in Entrada Therapeutics in the 2nd quarter worth approximately $230,000. Nantahala Capital Management LLC bought a new position in Entrada Therapeutics in the 2nd quarter worth about $2,212,232. Public Employees Retirement System of Ohio bought a new stake in shares of Entrada Therapeutics during the 2nd quarter valued at about $276,000. Bank of America Corp DE purchased a new position in shares of Entrada Therapeutics during the second quarter worth about $426,000. Finally, 5AM Venture Management LLC bought a new position in shares of Entrada Therapeutics in the second quarter worth approximately $29,854,949. Institutional investors own 86.39% of the company's stock.
About Entrada Therapeutics
(
Get Free Report)
Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.
The company's pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
